Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Multicenter Phase I/II Safety and Tolerability Study of Unilateral Vascular-Targeted Photodynamic Therapy Using WST11 in Patients With Localized Prostate Cancer

NCT00946881 is registered in ClinicalTrials.gov with Steba Biotech S.A. as lead sponsor.

NCT NCT00946881
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00946881 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Multicenter Phase I/II Safety and Tolerability Study of Unilateral Vascular-Targeted Photodynamic Therapy Using WST11 in Patients With Localized Prostate Cancer
Lead sponsor
Steba Biotech S.A.
Phase
Phase 1/2
Overall status
Completed
Start date
July 31, 2009
Completion date
August 31, 2012
Enrollment
30 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer